Loading the company…
Loading the company…
Families: Lumbar fusion, CSF shunts, Cholecystectomy & appendectomy, Cervical fusion & disc arthroplasty, Hernia repair.
All companies · Product and company coverage
In 2025, Aesculap reported engagement with 243 surgeons and other clinicians in the states MedaRep covers, worth $257K in consulting, speaking, meals and travel for its device products, the most in California ($41K to 26). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($41K, 26 engaged), Pennsylvania ($34K, 18 engaged), North Carolina ($30K, 11 engaged), Florida ($28K, 11 engaged), South Dakota ($21K, 6 engaged).
In the last ten years FDA made 7 decisions for Aesculap (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 5 procedure families, the most in 2019 (2). The latest was on 2026-10-02.
| Family | Decisions on record |
|---|---|
| Lumbar fusion | 24 |
| CSF shunts | 14 |
| Cholecystectomy & appendectomy | 14 |
| Cervical fusion & disc arthroplasty | 13 |
| Hernia repair | 2 |
| Miethke Shunt System GAV 2.0 and SA 2.0 Valves |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Aesculap.